| 王帅兵,郭 茜,刘 红.乳腺癌患者CYP2D6基因多态性与他莫昔芬疗效关系的研究进展[J].中国肿瘤,2021,30(7):539-544. |
| 乳腺癌患者CYP2D6基因多态性与他莫昔芬疗效关系的研究进展 |
| Research Progress on the Relationship Between CYP2D6 Gene Polymorphism and Tamoxifen Efficacy in Patients with Breast Cancer |
| 中文关键词 修订日期：2021-01-23 |
| DOI：10.11735/j.issn.1004-0242.2021.07.A010 |
|
 |
| 中文关键词: 乳腺癌 他莫昔芬 CYP2D6 基因多态性 |
| 英文关键词:breast cancer tamoxifen CYP2D6 gene polymorphism |
| 基金项目:河北省科技计划项目（182777147） |
|
| 摘要点击次数: 1477 |
| 全文下载次数: 301 |
| 中文摘要: |
| 摘 要：乳腺是女性激素的靶器官，雌激素与乳腺癌的发病密切相关，内分泌治疗是乳腺癌重要的治疗手段。对于雌激素受体（estrogen receptor，ER）阳性的患者，他莫昔芬（tamoxifen，TAM）是重要的内分泌治疗药物。但是TAM抗肿瘤作用微弱，需要经过体内代谢才能更好发挥作用。CYP2D6是TAM正常代谢的关键酶，具有多种基因多态性。CYP2D6基因多态性是否会影响TAM疗效，既往研究存在较大争议。该文回顾相关文献，就CYP2D6基因多态性与TAM疗效关系的进展作一综述。 |
| 英文摘要: |
| Abstract： Breast is the target organ of female hormone， and estrogen is closely related to the incidence of breast cancer. Endocrine therapy is an important treatment method for breast cancer， while Tamoxifen(TAM) is a wildly use medicine for estrogen receptor(ER) positive breast cancer patients. However， TAM exerting its anti-tumor effect need to be metabolized in vivo， and CYP2D6 is a key enzyme in the metabolism of TAM， which has multiple gene polymorphisms. Whether CYP2D6 gene polymorphism will affect the efficacy of TAM has been controversial. In this artical， the new progress about the association between CYP2D6 gene polymorphism and TAM efficacy is reviewed. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |